1. Home
  2. OP vs CDIO Comparison

OP vs CDIO Comparison

Compare OP & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OP
  • CDIO
  • Stock Information
  • Founded
  • OP 2021
  • CDIO 2017
  • Country
  • OP Greece
  • CDIO United States
  • Employees
  • OP N/A
  • CDIO N/A
  • Industry
  • OP
  • CDIO Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • OP
  • CDIO Health Care
  • Exchange
  • OP Nasdaq
  • CDIO Nasdaq
  • Market Cap
  • OP 8.3M
  • CDIO 23.6M
  • IPO Year
  • OP N/A
  • CDIO N/A
  • Fundamental
  • Price
  • OP $0.83
  • CDIO $0.38
  • Analyst Decision
  • OP
  • CDIO Buy
  • Analyst Count
  • OP 0
  • CDIO 1
  • Target Price
  • OP N/A
  • CDIO $2.00
  • AVG Volume (30 Days)
  • OP 9.6K
  • CDIO 827.6K
  • Earning Date
  • OP 04-10-2025
  • CDIO 05-14-2025
  • Dividend Yield
  • OP N/A
  • CDIO N/A
  • EPS Growth
  • OP N/A
  • CDIO N/A
  • EPS
  • OP N/A
  • CDIO N/A
  • Revenue
  • OP $25,729,000.00
  • CDIO $34,890.00
  • Revenue This Year
  • OP N/A
  • CDIO $1,434.82
  • Revenue Next Year
  • OP N/A
  • CDIO $4,661.91
  • P/E Ratio
  • OP N/A
  • CDIO N/A
  • Revenue Growth
  • OP 36.33
  • CDIO 104.45
  • 52 Week Low
  • OP $0.79
  • CDIO $0.19
  • 52 Week High
  • OP $3.10
  • CDIO $1.77
  • Technical
  • Relative Strength Index (RSI)
  • OP 29.76
  • CDIO 37.87
  • Support Level
  • OP $0.82
  • CDIO $0.30
  • Resistance Level
  • OP $0.92
  • CDIO $0.46
  • Average True Range (ATR)
  • OP 0.06
  • CDIO 0.04
  • MACD
  • OP -0.00
  • CDIO -0.00
  • Stochastic Oscillator
  • OP 22.68
  • CDIO 34.68

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.

About CDIO Cardio Diagnostics Holdings Inc. Common stock

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Share on Social Networks: